Seprehvec (STI1386) / Sorrento - LARVOL DELTA

OV2-RRST-101: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - P1b | N=36 | Not yet recruiting | Sponsor: Sorrento Therapeutics, Inc. | Trial completion date: Feb 2024 ➔ Feb 2027 | Initiation date: Jan 2023 ➔ Aug 2023 | Trial primary completion date: Apr 2023 ➔ Oct 2026

Oncolytic virus • Trial completion date • Trial initiation date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor

OV2-RRST-101: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - P1b | N=36 | Not yet recruiting | Sponsor: Sorrento Therapeutics, Inc. | Trial completion date: Mar 2025 ➔ Feb 2024 | Trial primary completion date: Dec 2024 ➔ Apr 2023

Oncolytic virus • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor

OV2-RRST-101: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - P1b | N=36 | Not yet recruiting | Sponsor: Sorrento Therapeutics, Inc. | Initiation date: Aug 2022 ➔ Nov 2022

Oncolytic virus • Trial initiation date • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - P1b | N=36 | Not yet recruiting | Sponsor: Sorrento Therapeutics, Inc.

New P1 trial • Oncolytic virus • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors (GlobeNewswire) - "Sorrento Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled 'Dose Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory Solid Tumors.'"

IND • Oncology

Breast cancer immunotherapy using magnetized HSV1716 (AACR 2019) - "Background: Oncolytic viruses (OV) are encouraging new immunotherapies for cancer. This study indicates that magnetizing HSV1716 results in viral protection from neutralizing antibodies and in combination with magnetic guidance reduces tumor burden and induces anti-tumor immunity."

Late-breaking abstract